First FDA-Approved Biologic Therapy for Psoriasis Becomes First in Canada
CAMBRIDGE, Mass., and SAN DIEGO, Oct. 13 /PRNewswire-FirstCall/ -- Biogen
Idec (Nasdaq: BIIB) today announced that Health Canada has authorized
AMEVIVE(R) (alefacept) for sale in Canada. AMEVIVE, the first biologic
approved for psoriasis in Canada, will be marketed for the treatment of
patients with moderate-to-severe chronic plaque psoriasis who are candidates
for systemic therapy or phototherapy.
(Logo: http://www.newscom.com/cgi-bin/prnh/20031112/LAW121LOGO )
AMEVIVE became the first approved biologic therapy for the treatment of
moderate-to-severe chronic plaque psoriasis in adults when it was approved in
the United States in 2003.
Biogen Idec creates new standards of care in oncology and immunology. As
a global leader in the development, manufacturing and commercialization of
novel therapies, Biogen Idec transforms scientific discoveries into advances
in human healthcare. For product labeling, press releases, and additional
information about the company, please visit http://www.biogenidec.com.
Media Contact:
Jose Juves
Associate Director, Public Affairs
Biogen Idec
(617) 914-6524
Investment Community Contact:
Christina Dillon
Senior Manager, Investor Relations
Biogen Idec
(617) 679-2812
SOURCE Biogen Idec
 back to top
Related links:
http://www.biogenidec.com
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20031112/LAW121LOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Media Contact: Jose Juves, Associate
Director, Public Affairs, +1-617-914-6524, or Investment
Community Contact: Christina Dillon, Senior Manager, Investor
Relations, +1-617-679-2812, both of Biogen Idec
|
